Madushini N Dharmasena, Manuel Osorio, Kazuyo Takeda, Scott Stibitz, Dennis J Kopecko
{"title":"Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.","authors":"Madushini N Dharmasena, Manuel Osorio, Kazuyo Takeda, Scott Stibitz, Dennis J Kopecko","doi":"10.1128/CVI.00181-17","DOIUrl":null,"url":null,"abstract":"<p><p>We have been exploring the use of the live attenuated <i>Salmonella enterica</i> serovar Typhi Ty21a vaccine strain as a versatile oral vaccine vector for the expression and delivery of multiple foreign antigens, including <i>Shigella</i> O-antigens. In this study, we separately cloned genes necessary for the biosynthesis of the <i>Shigella flexneri</i> serotype 2a and 3a O-antigens, which have been shown to provide broad cross-protection to multiple disease-predominant <i>S. flexneri</i> serotypes. The cloned <i>S. flexneri</i> 2a <i>rfb</i> operon, along with <i>bgt</i> and <i>gtrII</i>, contained on the SfII bacteriophage, was sufficient in Ty21a to express the heterologous <i>S. flexneri</i> 2a O-antigen containing the 3,4 antigenic determinants. Further, this <i>rfb</i> operon, along with <i>gtrA</i>, <i>gtrB</i>, and <i>gtrX</i> contained on the Sfx bacteriophage and <i>oac</i> contained on the Sf6 bacteriophage, was sufficient to express <i>S. flexneri</i> 3a O-antigen containing the 6, 7, and 8 antigenic determinants. Ty21a, with these plasmid-carried or chromosomally inserted genes, demonstrated simultaneous and stable expression of homologous <i>S</i> Typhi O-antigen plus the heterologous <i>S. flexneri</i> O-antigen. Candidate Ty21a vaccine strains expressing heterologous <i>S. flexneri</i> 2a or 3a lipopolysaccharide (LPS) elicited significant serum antibody responses against both homologous <i>S</i> Typhi and heterologous <i>Shigella</i> LPS and protected mice against virulent <i>S. flexneri</i> 2a or 3a challenges. These new <i>S. flexneri</i> 2a and 3a O-antigen-expressing Ty21a vaccine strains, together with our previously constructed Ty21a strains expressing <i>Shigella sonnei</i> or <i>Shigella dysenteriae</i> 1 O-antigens, have the potential to be used together for simultaneous protection against the predominant causes of shigellosis worldwide as well as against typhoid fever.</p>","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1128/CVI.00181-17","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/CVI.00181-17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/12/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 16
Abstract
We have been exploring the use of the live attenuated Salmonella enterica serovar Typhi Ty21a vaccine strain as a versatile oral vaccine vector for the expression and delivery of multiple foreign antigens, including Shigella O-antigens. In this study, we separately cloned genes necessary for the biosynthesis of the Shigella flexneri serotype 2a and 3a O-antigens, which have been shown to provide broad cross-protection to multiple disease-predominant S. flexneri serotypes. The cloned S. flexneri 2a rfb operon, along with bgt and gtrII, contained on the SfII bacteriophage, was sufficient in Ty21a to express the heterologous S. flexneri 2a O-antigen containing the 3,4 antigenic determinants. Further, this rfb operon, along with gtrA, gtrB, and gtrX contained on the Sfx bacteriophage and oac contained on the Sf6 bacteriophage, was sufficient to express S. flexneri 3a O-antigen containing the 6, 7, and 8 antigenic determinants. Ty21a, with these plasmid-carried or chromosomally inserted genes, demonstrated simultaneous and stable expression of homologous S Typhi O-antigen plus the heterologous S. flexneri O-antigen. Candidate Ty21a vaccine strains expressing heterologous S. flexneri 2a or 3a lipopolysaccharide (LPS) elicited significant serum antibody responses against both homologous S Typhi and heterologous Shigella LPS and protected mice against virulent S. flexneri 2a or 3a challenges. These new S. flexneri 2a and 3a O-antigen-expressing Ty21a vaccine strains, together with our previously constructed Ty21a strains expressing Shigella sonnei or Shigella dysenteriae 1 O-antigens, have the potential to be used together for simultaneous protection against the predominant causes of shigellosis worldwide as well as against typhoid fever.
期刊介绍：
Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
